Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of “Hold” from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has been given an average recommendation of “Hold” by the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $15.17.

ELAN has been the topic of several research reports. UBS Group dropped their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus upped their target price on Elanco Animal Health from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Monday. Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Piper Sandler decreased their price objective on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Finally, Morgan Stanley lowered their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th.

Insider Activity at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the transaction, the director now directly owns 101,459 shares in the company, valued at approximately $1,105,903.10. This represents a 10.93% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 0.89% of the stock is currently owned by insiders.

Institutional Trading of Elanco Animal Health

Several hedge funds have recently made changes to their positions in ELAN. Allworth Financial LP lifted its position in Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock valued at $25,000 after purchasing an additional 2,090 shares during the period. CoreCap Advisors LLC acquired a new position in Elanco Animal Health during the fourth quarter worth $29,000. Parallel Advisors LLC raised its position in Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock worth $41,000 after acquiring an additional 1,852 shares in the last quarter. NBC Securities Inc. acquired a new stake in Elanco Animal Health in the first quarter valued at $40,000. Finally, Jones Financial Companies Lllp grew its stake in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after purchasing an additional 2,059 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

ELAN stock opened at $12.64 on Thursday. The business has a 50 day moving average price of $10.26 and a 200 day moving average price of $11.45. The stock has a market cap of $6.28 billion, a price-to-earnings ratio of 31.59, a PEG ratio of 2.50 and a beta of 1.49. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter last year, the company earned $0.34 earnings per share. The firm’s revenue for the quarter was down 1.0% on a year-over-year basis. Equities research analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.